{"pmid":32443810,"title":"A Structural View of SARS-CoV-2 RNA Replication Machinery: RNA Synthesis, Proofreading and Final Capping.","text":["A Structural View of SARS-CoV-2 RNA Replication Machinery: RNA Synthesis, Proofreading and Final Capping.","The current coronavirus disease-2019 (COVID-19) pandemic is due to the novel coronavirus SARS-CoV-2. The scientific community has mounted a strong response by accelerating research and innovation, and has quickly set the foundation for understanding the molecular determinants of the disease for the development of targeted therapeutic interventions. The replication of the viral genome within the infected cells is a key stage of the SARS-CoV-2 life cycle. It is a complex process involving the action of several viral and host proteins in order to perform RNA polymerization, proofreading and final capping. This review provides an update of the structural and functional data on the key actors of the replicatory machinery of SARS-CoV-2, to fill the gaps in the currently available structural data, which is mainly obtained through homology modeling. Moreover, learning from similar viruses, we collect data from the literature to reconstruct the pattern of interactions among the protein actors of the SARS-CoV-2 RNA polymerase machinery. Here, an important role is played by co-factors such as Nsp8 and Nsp10, not only as allosteric activators but also as molecular connectors that hold the entire machinery together to enhance the efficiency of RNA replication.","Cells","Romano, Maria","Ruggiero, Alessia","Squeglia, Flavia","Maga, Giovanni","Berisio, Rita","32443810"],"abstract":["The current coronavirus disease-2019 (COVID-19) pandemic is due to the novel coronavirus SARS-CoV-2. The scientific community has mounted a strong response by accelerating research and innovation, and has quickly set the foundation for understanding the molecular determinants of the disease for the development of targeted therapeutic interventions. The replication of the viral genome within the infected cells is a key stage of the SARS-CoV-2 life cycle. It is a complex process involving the action of several viral and host proteins in order to perform RNA polymerization, proofreading and final capping. This review provides an update of the structural and functional data on the key actors of the replicatory machinery of SARS-CoV-2, to fill the gaps in the currently available structural data, which is mainly obtained through homology modeling. Moreover, learning from similar viruses, we collect data from the literature to reconstruct the pattern of interactions among the protein actors of the SARS-CoV-2 RNA polymerase machinery. Here, an important role is played by co-factors such as Nsp8 and Nsp10, not only as allosteric activators but also as molecular connectors that hold the entire machinery together to enhance the efficiency of RNA replication."],"journal":"Cells","authors":["Romano, Maria","Ruggiero, Alessia","Squeglia, Flavia","Maga, Giovanni","Berisio, Rita"],"date":"2020-05-24T11:00:00Z","year":2020,"_id":"32443810","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.3390/cells9051267","keywords":["covid19","rna replication","sars-cov-2","infectious disease","protein structure"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1667600475823800321,"score":9.490897,"similar":[{"pmid":32416679,"title":"Novel Drugs Targeting the SARS-CoV-2/COVID-19 Machinery.","text":["Novel Drugs Targeting the SARS-CoV-2/COVID-19 Machinery.","Like other human pathogenic viruses, coronavirus SARS-CoV-2 employs sophisticated macromolecular machines for viral host cell entry, genome replication and protein processing. Such machinery encompasses SARS-CoV-2 envelope spike (S) glycoprotein required for host cell entry by binding to the ACE2 receptor, viral RNA-dependent RNA polymerase (RdRp) and 3-chymotrypsin-like main protease (3Clpro/Mpro). Under the pressure of the accelerating COVID-19 pandemic caused by the outbreak of SARSCoV- 2 in Wuhan, China in December 2019, novel and repurposed drugs were recently designed and identified for targeting the SARS-CoV-2 reproduction machinery, with the aim to limit spread of SARS-CoV-2 and morbidity and mortality of the COVID-19 pandemic.","Curr Top Med Chem","Sternberg, Ariane","McKee, Dwight L","Naujokat, Cord","32416679"],"abstract":["Like other human pathogenic viruses, coronavirus SARS-CoV-2 employs sophisticated macromolecular machines for viral host cell entry, genome replication and protein processing. Such machinery encompasses SARS-CoV-2 envelope spike (S) glycoprotein required for host cell entry by binding to the ACE2 receptor, viral RNA-dependent RNA polymerase (RdRp) and 3-chymotrypsin-like main protease (3Clpro/Mpro). Under the pressure of the accelerating COVID-19 pandemic caused by the outbreak of SARSCoV- 2 in Wuhan, China in December 2019, novel and repurposed drugs were recently designed and identified for targeting the SARS-CoV-2 reproduction machinery, with the aim to limit spread of SARS-CoV-2 and morbidity and mortality of the COVID-19 pandemic."],"journal":"Curr Top Med Chem","authors":["Sternberg, Ariane","McKee, Dwight L","Naujokat, Cord"],"date":"2020-05-18T11:00:00Z","year":2020,"_id":"32416679","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.2174/1568026620999200517043137","keywords":["3clpro","covid-19","camostat","coronavirus sars-cov-2","rna polymerase","remdesivir","s protein","alpha-ketoamides."],"locations":["Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1667058206742937600,"score":342.70105},{"pmid":32277040,"pmcid":"PMC7164392","title":"Structure of the RNA-dependent RNA polymerase from COVID-19 virus.","text":["Structure of the RNA-dependent RNA polymerase from COVID-19 virus.","A novel coronavirus (COVID-19 virus) outbreak has caused a global pandemic resulting in tens of thousands of infections and thousands of deaths worldwide. The RNA-dependent RNA polymerase (RdRp, also named nsp12) is the central component of coronaviral replication/transcription machinery and appears to be a primary target for the antiviral drug, remdesivir. We report the cryo-EM structure of COVID-19 virus full-length nsp12 in complex with cofactors nsp7 and nsp8 at 2.9-A resolution. In addition to the conserved architecture of the polymerase core of the viral polymerase family, nsp12 possesses a newly identified beta-hairpin domain at its N terminus. A comparative analysis model shows how remdesivir binds to this polymerase. The structure provides a basis for the design of new antiviral therapeutics targeting viral RdRp.","Science","Gao, Yan","Yan, Liming","Huang, Yucen","Liu, Fengjiang","Zhao, Yao","Cao, Lin","Wang, Tao","Sun, Qianqian","Ming, Zhenhua","Zhang, Lianqi","Ge, Ji","Zheng, Litao","Zhang, Ying","Wang, Haofeng","Zhu, Yan","Zhu, Chen","Hu, Tianyu","Hua, Tian","Zhang, Bing","Yang, Xiuna","Li, Jun","Yang, Haitao","Liu, Zhijie","Xu, Wenqing","Guddat, Luke W","Wang, Quan","Lou, Zhiyong","Rao, Zihe","32277040"],"abstract":["A novel coronavirus (COVID-19 virus) outbreak has caused a global pandemic resulting in tens of thousands of infections and thousands of deaths worldwide. The RNA-dependent RNA polymerase (RdRp, also named nsp12) is the central component of coronaviral replication/transcription machinery and appears to be a primary target for the antiviral drug, remdesivir. We report the cryo-EM structure of COVID-19 virus full-length nsp12 in complex with cofactors nsp7 and nsp8 at 2.9-A resolution. In addition to the conserved architecture of the polymerase core of the viral polymerase family, nsp12 possesses a newly identified beta-hairpin domain at its N terminus. A comparative analysis model shows how remdesivir binds to this polymerase. The structure provides a basis for the design of new antiviral therapeutics targeting viral RdRp."],"journal":"Science","authors":["Gao, Yan","Yan, Liming","Huang, Yucen","Liu, Fengjiang","Zhao, Yao","Cao, Lin","Wang, Tao","Sun, Qianqian","Ming, Zhenhua","Zhang, Lianqi","Ge, Ji","Zheng, Litao","Zhang, Ying","Wang, Haofeng","Zhu, Yan","Zhu, Chen","Hu, Tianyu","Hua, Tian","Zhang, Bing","Yang, Xiuna","Li, Jun","Yang, Haitao","Liu, Zhijie","Xu, Wenqing","Guddat, Luke W","Wang, Quan","Lou, Zhiyong","Rao, Zihe"],"date":"2020-04-12T11:00:00Z","year":2020,"_id":"32277040","source":"PubMed","week":"202015|Apr 06 - Apr 12","doi":"10.1126/science.abb7498","e_drugs":["remdesivir"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1666138491615969280,"score":329.9077},{"pmid":32397643,"title":"Potential Drugs Targeting Early Innate Immune Evasion of SARS-Coronavirus 2 via 2'-O-Methylation of Viral RNA.","text":["Potential Drugs Targeting Early Innate Immune Evasion of SARS-Coronavirus 2 via 2'-O-Methylation of Viral RNA.","The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) causing the COVID-19 respiratory disease pandemic utilizes unique 2'-O-methyltransferase (2'-O-MTase) capping machinery to camouflage its RNA from innate immune recognition. The nsp16 catalytic subunit of the 2'-O-MTase is unusual in its requirement for a stimulatory subunit (nsp10) to catalyze the ribose 2'-O-methylation of the viral RNA cap. Here we provide a computational basis for drug repositioning or de novo drug development based on three differential traits of the intermolecular interactions of the SARS-CoV-2-specific nsp16/nsp10 heterodimer, namely: (1) the S-adenosyl-l-methionine-binding pocket of nsp16, (2) the unique \"activating surface\" between nsp16 and nsp10, and (3) the RNA-binding groove of nsp16. We employed approximately 9000 U.S. Food and Drug Administration (FDA)-approved investigational and experimental drugs from the DrugBank repository for docking virtual screening. After molecular dynamics calculations of the stability of the binding modes of high-scoring nsp16/nsp10-drug complexes, we considered their pharmacological overlapping with functional modules of the virus-host interactome that is relevant to the viral lifecycle, and to the clinical features of COVID-19. Some of the predicted drugs (e.g., tegobuvir, sonidegib, siramesine, antrafenine, bemcentinib, itacitinib, or phthalocyanine) might be suitable for repurposing to pharmacologically reactivate innate immune restriction and antagonism of SARS-CoV-2 RNAs lacking 2'-O-methylation.","Viruses","Encinar, Jose Antonio","Menendez, Javier A","32397643"],"abstract":["The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) causing the COVID-19 respiratory disease pandemic utilizes unique 2'-O-methyltransferase (2'-O-MTase) capping machinery to camouflage its RNA from innate immune recognition. The nsp16 catalytic subunit of the 2'-O-MTase is unusual in its requirement for a stimulatory subunit (nsp10) to catalyze the ribose 2'-O-methylation of the viral RNA cap. Here we provide a computational basis for drug repositioning or de novo drug development based on three differential traits of the intermolecular interactions of the SARS-CoV-2-specific nsp16/nsp10 heterodimer, namely: (1) the S-adenosyl-l-methionine-binding pocket of nsp16, (2) the unique \"activating surface\" between nsp16 and nsp10, and (3) the RNA-binding groove of nsp16. We employed approximately 9000 U.S. Food and Drug Administration (FDA)-approved investigational and experimental drugs from the DrugBank repository for docking virtual screening. After molecular dynamics calculations of the stability of the binding modes of high-scoring nsp16/nsp10-drug complexes, we considered their pharmacological overlapping with functional modules of the virus-host interactome that is relevant to the viral lifecycle, and to the clinical features of COVID-19. Some of the predicted drugs (e.g., tegobuvir, sonidegib, siramesine, antrafenine, bemcentinib, itacitinib, or phthalocyanine) might be suitable for repurposing to pharmacologically reactivate innate immune restriction and antagonism of SARS-CoV-2 RNAs lacking 2'-O-methylation."],"journal":"Viruses","authors":["Encinar, Jose Antonio","Menendez, Javier A"],"date":"2020-05-14T11:00:00Z","year":2020,"_id":"32397643","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.3390/v12050525","keywords":["covid-19","computational screening","drug repurposing","methylation","methyltransferases","molecular docking","molecular dynamics"],"locations":["tegobuvir","sonidegib","siramesine","antrafenine","bemcentinib","itacitinib","phthalocyanine"],"e_drugs":["Lu 28-179","sonidegib","tegobuvir","INCB039110","Methionine","phthalocyanine","Ribose","antrafenine"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666714494758289408,"score":301.40634},{"pmid":32438371,"title":"Structure of replicating SARS-CoV-2 polymerase.","text":["Structure of replicating SARS-CoV-2 polymerase.","The coronavirus SARS-CoV-2 uses an RNA-dependent RNA polymerase (RdRp) for the replication of its genome and the transcription of its genes(1-3). Here we present the cryo-electron microscopic structure of the SARS-CoV-2 RdRp in active form, mimicking the replicating enzyme. The structure comprises the viral proteins nsp12, nsp8, and nsp7, and over two turns of RNA template-product duplex. The active site cleft of nsp12 binds the first turn of RNA and mediates RdRp activity with conserved residues. Two copies of nsp8 bind to opposite sides of the cleft and position the second turn of RNA. Long helical extensions in nsp8 protrude along exiting RNA, forming positively charged 'sliding poles'. These sliding poles can account for the known processivity of the RdRp that is required for replicating the long coronavirus genome(3). Our results enable a detailed analysis of the inhibitory mechanisms that underlie the antiviral activity of substances such as remdesivir, a drug for the treatment of coronavirus disease 2019 (COVID-19)(4).","Nature","Hillen, Hauke S","Kokic, Goran","Farnung, Lucas","Dienemann, Christian","Tegunov, Dimitry","Cramer, Patrick","32438371"],"abstract":["The coronavirus SARS-CoV-2 uses an RNA-dependent RNA polymerase (RdRp) for the replication of its genome and the transcription of its genes(1-3). Here we present the cryo-electron microscopic structure of the SARS-CoV-2 RdRp in active form, mimicking the replicating enzyme. The structure comprises the viral proteins nsp12, nsp8, and nsp7, and over two turns of RNA template-product duplex. The active site cleft of nsp12 binds the first turn of RNA and mediates RdRp activity with conserved residues. Two copies of nsp8 bind to opposite sides of the cleft and position the second turn of RNA. Long helical extensions in nsp8 protrude along exiting RNA, forming positively charged 'sliding poles'. These sliding poles can account for the known processivity of the RdRp that is required for replicating the long coronavirus genome(3). Our results enable a detailed analysis of the inhibitory mechanisms that underlie the antiviral activity of substances such as remdesivir, a drug for the treatment of coronavirus disease 2019 (COVID-19)(4)."],"journal":"Nature","authors":["Hillen, Hauke S","Kokic, Goran","Farnung, Lucas","Dienemann, Christian","Tegunov, Dimitry","Cramer, Patrick"],"date":"2020-05-22T11:00:00Z","year":2020,"_id":"32438371","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1038/s41586-020-2368-8","e_drugs":["remdesivir"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1667521393648992256,"score":279.64725},{"pmid":32363136,"pmcid":"PMC7194921","title":"Crystal structure of SARS-CoV-2 nucleocapsid protein RNA binding domain reveals potential unique drug targeting sites.","text":["Crystal structure of SARS-CoV-2 nucleocapsid protein RNA binding domain reveals potential unique drug targeting sites.","The outbreak of coronavirus disease (COVID-19) caused by SARS-CoV-2 virus continually led to worldwide human infections and deaths. Currently, there is no specific viral protein-targeted therapeutics. Viral nucleocapsid protein is a potential antiviral drug target, serving multiple critical functions during the viral life cycle. However, the structural information of SARS-CoV-2 nucleocapsid protein remains unclear. Herein, we have determined the 2.7 A crystal structure of the N-terminal RNA binding domain of SARS-CoV-2 nucleocapsid protein. Although the overall structure is similar as other reported coronavirus nucleocapsid protein N-terminal domain, the surface electrostatic potential characteristics between them are distinct. Further comparison with mild virus type HCoV-OC43 equivalent domain demonstrates a unique potential RNA binding pocket alongside the beta-sheet core. Complemented by in vitro binding studies, our data provide several atomic resolution features of SARS-CoV-2 nucleocapsid protein N-terminal domain, guiding the design of novel antiviral agents specific targeting to SARS-CoV-2.","Acta Pharm Sin B","Kang, Sisi","Yang, Mei","Hong, Zhongsi","Zhang, Liping","Huang, Zhaoxia","Chen, Xiaoxue","He, Suhua","Zhou, Ziliang","Zhou, Zhechong","Chen, Qiuyue","Yan, Yan","Zhang, Changsheng","Shan, Hong","Chen, Shoudeng","32363136"],"abstract":["The outbreak of coronavirus disease (COVID-19) caused by SARS-CoV-2 virus continually led to worldwide human infections and deaths. Currently, there is no specific viral protein-targeted therapeutics. Viral nucleocapsid protein is a potential antiviral drug target, serving multiple critical functions during the viral life cycle. However, the structural information of SARS-CoV-2 nucleocapsid protein remains unclear. Herein, we have determined the 2.7 A crystal structure of the N-terminal RNA binding domain of SARS-CoV-2 nucleocapsid protein. Although the overall structure is similar as other reported coronavirus nucleocapsid protein N-terminal domain, the surface electrostatic potential characteristics between them are distinct. Further comparison with mild virus type HCoV-OC43 equivalent domain demonstrates a unique potential RNA binding pocket alongside the beta-sheet core. Complemented by in vitro binding studies, our data provide several atomic resolution features of SARS-CoV-2 nucleocapsid protein N-terminal domain, guiding the design of novel antiviral agents specific targeting to SARS-CoV-2."],"journal":"Acta Pharm Sin B","authors":["Kang, Sisi","Yang, Mei","Hong, Zhongsi","Zhang, Liping","Huang, Zhaoxia","Chen, Xiaoxue","He, Suhua","Zhou, Ziliang","Zhou, Zhechong","Chen, Qiuyue","Yan, Yan","Zhang, Changsheng","Shan, Hong","Chen, Shoudeng"],"date":"2020-05-05T11:00:00Z","year":2020,"_id":"32363136","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1016/j.apsb.2020.04.009","keywords":["antiviral targeting site","covid-19","coronavirus","crystal structure","nucleocapsid protein","rna binding domain","sars-cov-2"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666138496012648449,"score":257.21854}]}